Ascendis Pharma AS (NAS:ASND)
$ 137.5 -2.81 (-2%) Market Cap: 8.39 Bil Enterprise Value: 8.62 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 71/100

Ascendis Pharma A/S at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 05:30PM GMT
Release Date Price: $102.7 (-0.88%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst

Welcome. Let's go ahead and get started. This is the fireside chat with Ascendis Pharma. My name is Vikram Purohit and I'm one of the Biotech Analyst with Morgan Stanley Research. I need to read a brief disclosure before we get started. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative.

With that, let's get started. Happy to have with me Jan Mikkelsen, CEO; Scott Smith, CFO; and Tim Lee, Investor Relations from Ascendis Pharma. Thank you for joining us.

Questions & Answers

Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst

Jan, maybe just to start off with, could you give us some opening remarks on just a quick overview of the business and recap some of the key achievements that you think the company

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot